Content uploaded by Nikolaos Panagiotou
Author content
All content in this area was uploaded by Nikolaos Panagiotou on Oct 12, 2023
Content may be subject to copyright.
Results
Results reveal that the frequencies for most SNPs (Table 1) in the genotyped samples are
consistent with European population frequencies. Moreover, 96.2% of the sub-group of
patients with MDD (n=132) answered positively to the question «Response to treatment after
PGx» (p<0.01) (Fig. 1). Interestingly, most of the patients (82.6%) didn’t report severe side
effects (Fig. 2), 90.5% of patients referred that it was necessary to change the previous
treatment after PGx CNS test (Fig. 3) and87.1% reported that they had less visits &
communications with the doctor after iDNA PGx-CNS test was conducted (p<0.01) (Fig. 4).
These results are indicative of the significant potential of this PGx-CNS panel as an in vitro
diagnostic device to enable personalized medicine. for neurological disorders.
Methods
For the development of the pharmacogenetic
panel, 24 SNPs on 13 genes were selected and
analyzed, employing a bioinformatic platform
which contains an in house PGx-CNS database, to
provide individualized pharmacogenetic
information about metabolism, response, efficacy
and adverse events related to 31 drugs. This
platform was used for the analysis of 2075
patient-derived samples from a southeastern
European population. Subsequently, a sub-group
of 132 patients, who received a diagnosis of MDD,
were questioned for their response to received
medication, if there were any severe side effects,
changes in their previous medication and reduced
number of visits & communications with the
physician after iDNA PGx-CNS test use.
A novel pharmacogenetic test supports drug selection for diseases of the Central Nervous System
E. Ntoumou1, *, N. Panagiotou1, E. Bothos2,3, D. Roukas4, N. Drakoulis5, M. Papasavva5, F.A. Karakostis6, P. Moulos2,7, K. Karakostis1
1iDNA Genomics, Evrota 25, Kifissia, 145 64, Greece; 2Genolytica G.P., Greece; 3Institute of Communications and Computer Systems, National Technical University of Athens, Greece; 4Department of Psychiatry, 417 Veterans Army Hospital (NIMTS), 115 21 Athens, Greece;
5Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15771 Zografou; 6Paleoanthropology, Senckenberg Centre for Human Evolution and
Palaeoenvironment, Department of Geosciences, University of Tübingen, Tübingen, Germany; 7Institute for Fundamental Biomedical Research, Biomedical Sciences Research Center ‘Alexander Fleming’, 34 Fleming str, 16672, Vari, Greece
Background
Pharmacogenetics (PGx) study the
interaction between drugs and gene
variation with the aim to improve and
personalize clinical management of health
disorders. Here, we present a novel
pharmacogenetic panel (iDNA PGx-CNS)
that provides clinically useful information
to Psychiatrists for optimizing the selection
of the most appropriate medication for
neurological disorders, such as Major
Depressive Disorder (MDD) and
Schizophrenia. Moreover, we evaluated the
utility of iDNA PGx-CNS in the support of
clinical decisions related to drug selection.
Copyright © 2022
Conclusion
Overall, the results strongly suggest that the iDNA PGx-CNS test is a valuable tool
providing useful pharmacogenetic-based clinical information to Psychiatrists,
supporting therapeutic medical decisions for MDD, thus urging its broader clinical
implementation to personalized medicine.
Fig 1. Response to treatment after PGX Fig 2.Severe side effects
Response to treatment
Percent (%)
Severe side effects
References:
Bothos et al.J Transl Med, 2021, 19(1), 151.
Roukas et al.European Neuropsychopharmacology, 53, S159-S160.
Table 1. Genotype frequencies
Fig 3. Was it necessary to change the
previous treatment after PGx?
Fig 4. Less visits & communications with the
doctor after PGx use
Percent (%)